구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | GM103 (Part B) |
Overview Company | GeneMedicine Co., Ltd. |
Overview Modality | CGT |
Overview Target | Head and Neck Cancer |
Overview Indication | Head and Neck Cancer; Malignant Melanoma |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
PK/PD Half-life | 53 h |
Toxicology Major finding | First-in-Human Dose Selection and Safety, Tolerability, Pharmacokinetics, and Immunogenicity of the Muscle-Specific Kinase Agonist Adimanebart (ARGX-119).. Adimanebart (ARGX-119), a first-in-class, humanized, agonistic monoclonal antibody, specifically targets and activates muscle-specific kinase, stabilizing the neuromuscular junction, increasing muscle strength, and decreasing muscle weakness an… |
Clinical Safety signal | First-in-Human Dose Selection and Safety, Tolerability, Pharmacokinetics, and Immunogenicity of the Muscle-Specific Kinase Agonist Adimanebart (ARGX-119).. Adimanebart (ARGX-119), a first-in-class, humanized, agonistic monoclonal antibody, specifically targets and activates muscle-specific kinase, stabilizing the neuromuscular junction, increasing muscle strength, and decreasing muscle weakness an… |
Clinical Selected reported efficacy | ORR 15.093% |
Clinical Reported ORR | -15.093 |
Clinical Result source | ClinicalTrials.gov NCT02706886 |
Clinical Program phase | PHASE_2 |
Clinical Trial ref | NCT02706886 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | GM103 (Part B) |
Overview Company | GeneMedicine Co., Ltd. |
Overview Modality | CGT |
Overview Target | Head and Neck Cancer |
Overview Indication | Head and Neck Cancer; Malignant Melanoma |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
PK/PD Half-life | 53 h |
Toxicology Major finding | First-in-Human Dose Selection and Safety, Tolerability, Pharmacokinetics, and Immunogenicity of the Muscle-Specific Kinase Agonist Adimanebart (ARGX-119).. Adimanebart (ARGX-119), a first-in-class, humanized, agonistic monoclonal antibody, specifically targets and activates muscle-specific kinase, stabilizing the neuromuscular junction, increasing muscle strength, and decreasing muscle weakness an… |
Clinical Safety signal | First-in-Human Dose Selection and Safety, Tolerability, Pharmacokinetics, and Immunogenicity of the Muscle-Specific Kinase Agonist Adimanebart (ARGX-119).. Adimanebart (ARGX-119), a first-in-class, humanized, agonistic monoclonal antibody, specifically targets and activates muscle-specific kinase, stabilizing the neuromuscular junction, increasing muscle strength, and decreasing muscle weakness an… |
Clinical Selected reported efficacy | ORR 15.093% |
Clinical Reported ORR | -15.093 |
Clinical Result source | ClinicalTrials.gov NCT02706886 |
Clinical Program phase | PHASE_2 |
Clinical Trial ref | NCT02706886 |
추천 비교
추천 비교